DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183904

A study of profile of patients failing first line NACO recommended ART

Mahim Mittal, Phool Chand, Ashootosh Kumar Mall

Abstract


Background: Failure of first line NACO recommended Therapy has been reported in 1-5% cases of HIV/AIDS. Various factors are associated with failure. This study describes the profile of patients failing first line ART (FLA) in a predominately lower socioeconomic population. The objective of the present study was to identify factors associated with failure of FLA.

Methods: Retrospective data analysis of patients failing first line therapy. Epidemiological information, clinical parameters and laboratory reports were taken into consideration. Data was analysed as per standard statistical analysis.

Results: Out of a total 3926 patients on first line ART for varying periods of time from our ART centre 54 patients were on second line ART. Males (2.20%) had a high failure rate than females (0.50%). The average time of failure was 64.11 months with a median of 56.50 months. 74.1% (40/54) of the patients had very low CD4 count at the time of initial diagnosis. Failure rate of FLA was higher in the patients having Stavudine based regimen (NRTI) (6.61%) and 3.64% in patients having Nevirapine based regimen (NNRTI).

Conclusions: Second line therapy is required only in a small number of patients at present, but as it is related to the duration on first line ART and also with initial low CD4 count, more and more patients will require SLA in the near future.


Keywords


FLA (first line antiretroviral), NNRTI (non-nucleoside reverse transcriptase inhibitor), NRTI (nucleoside/nucleotide reverse transcriptase inhibitors), SLA (second line antiretroviral), VL (viral load)

Full Text:

PDF

References


National Aids Control Organisation, Ministry of Health and Fw, Govt of India. NACO annual report. 2017;24:3-4. Available at http://naco.gov.in/sites/default/files/NACO%20ANNUAL%20REPORT%202016-17.pdf.

National Aids Control Organisation Ministry Of Health & Fw, Govt Of India. National Guidelines on Second-line and Alternative First-line ART For Adults and Adolescents. 2013; P.7. Available at: http://naco.gov.in/sites/default/files/National%20Guidelines%20on%20Second-line%20and%20 Alternative%20First-line%20ART%20For%20 Adults%20and%20Adolescents.%20May"http://naco.gov.in/sites/default/files/National Guidelines on Second-line and Alternative First-line ART For Adults and Adolescents. 2013.pdf.

Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proceed National Acad Sci. 2002 Oct 29;99(22):14410-5.

Yerly S, Kaiser L, Race EE, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet. 1999 Aug 28;354(9180):729-33.

Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011 Aug 18;365(7):637-46.

Government of the Republic of Zambia. Ministry of Health. National Guidelines on Management and Care for HIV/AIDS. 2004:52. Available at http://apps.who.int/medicinedocs/documents/s17758en/s17758en.pdf

Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. Aids. 2010 Mar 27;24(6):915-9.

UNOCHA. Govt moves to earlier HIV treatment. 2011. Plus News Johannesburg, South Africa. Available at http://www.plusnews.org/PrintReport.aspx?ReportID=93500.

Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub‐Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010 Jun 1;15:1-5.

Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010 Feb 20;24(4):563-72.

Fox MP, Van Cutsem G, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquired Immune Def Syndromes. 2012 Aug 1;60(4):428-37.

Hosseinipour MC, Van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009 Jun 1;23(9):1127-34.

Datay MI, Boulle A, Mant D, Yudkin P. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquired Immune Def Syndromes. 2010; 54(5):489-95.

Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa J Acquired Immune Def Syndromes. 2011 Sep 1;58(1):23-31.

Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first-and second-line antiretroviral therapy in resource-limited settings. J Infectious Dis. 2013 Jun 15;207(suppl_2):S49-56.

Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy. Clin Infect Dis. 2009 Dec 15;49(12):1928-35.

Rajasekaran S, Jeyaseelan L, Vijila S, Gomathi C, Raja K. Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience. AIDS. 2007 Jul 1;21:S47-53.

Patrikar S, Shankar S, Kotwal A, Basannar DR, Bhatti V, Verma R, et al. Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy. Med J Armed Forces India. 2017 Jan 1;73(1):5-11.

Anup S, Amit A, Jaya C, Sarita K, Madhukar R, Shyam S. Predictive markers of failure of first line anti-retroviral treatment in HIV patients in India. J AIDS Clin Res. 2013;4(5):210.

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013;7:134. Available at http://www.who.int/hiv/pub/guidelines/arv2013/art/arv2013_chapter07_low.pdf.

Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012 May 15;26(8):929-38.

Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, Phillips A, et al. Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One. 2012 May 29;7(5):e36997.

Onyedum CC, Iroezindu MO, Chukwuka CJ, Anyaene CE, Obi FI, et al. Profile of HIV-infected patients receiving second-line antiretroviral therapy in a resource-limited setting in Nigeria. Transactions Royal Soc Trop Med Hygiene. 2013 Aug 19;107(10):608-14.

Kipp W, Alibhai A, Saunders LD, Senthilselvan A, Kaler A, Konde-Lule J, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS care. 2010 Mar 1;22(3):271-8.

Penot P, Héma A, Bado G, Kaboré F, Soré I, Sombié D, et al. The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso. J Int AIDS Soc. 2014 Jan;17(1):18646.

Patrikar S, Subramaniam S, Vasudevan B, Bhatti V, Kotwal A. Profile of HIV Patients on Second Line Antiretroviral Therapy: The Indian Experience. J AIDS Clin Res. 2015;6(459):2.

Singh A, Chakravarty J, Gupta A, Sundar S, Rai M, Singh A, et al. Response to second line antiretroviral therapy in India. BMC Infect Dis. 2012;12(Suppl 1):40.

Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, et al, DREAM Program. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis. 2009 Jan 1;48(1):115-22.

Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R. Early outcomes and the virologic impact of delayed treatment switching on second-line therapy in an antiretroviral roll-out program in South Africa. Antiviral Therapy. 2011;16(6):853.

Babo YD, Alemie GA, Fentaye FW. Predictors of first-line antiretroviral therapy failure amongst HIV-infected adult clients at Woldia Hospital, Northeast Ethiopia. PloS One. 2017 Nov 2;12(11):e0187694.

Yayehirad AM, Mamo WT, Gizachew AT, Tadesse AA. Rate of immunological failure and its predictors among patients on highly active antiretroviral therapy at Debremarkos hospital, Northwest Ethiopia: a retrospective follow up study. J AIDS Clin Res. 2013;4(5).

Teshome W, Assefa A. Predictors of immunological failure of antiretroviral therapy among HIV infected patients in Ethiopia: a matched case-control study. PLoS One. 2014 Dec 23;9(12):e115125.

Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009 Dec;9(1):81.

Prabhakar B, Banu A, Pavithra HB, Chandrashekhara P, Sasthri S. Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. Indian J Sexually Transmitted Dis. 2011 Jul;32(2):94.

Meriki HD, Tufon KA, Afegenwi MH, Nyindem BA, Atanga PN, Anong DN, et al. Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon. Infect Dis Poverty. 2014 Jan;3(1):5.

Kwobah CM, Mwangi AW, Koech JK, Simiyu GN, Siika AM. Factors associated with first-line antiretroviral therapy failure amongst HIV-infected African patients: a case-control study. World J AIDS. 2012 Dec 10;2(4):271-8.

Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994 Apr 1;169(4):722-9.

Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceed Nat Acad Sci, USA 1995; 92:2398-402.

Kavlick MF, Kathleen W, Robert Y, Hiroaki M. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Infect Dis. 1998 Jun 1;177(6):1506-13.

Bloor S, Hertogs K, Desmer RL, Pauwels R, Larder BA. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples. Antiviral Therapy. 1998 Jun;3(Suppl 1):13-4.

Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis. 1994 Nov 1;170(5):1157-64.